Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Abstract B207: Nivolumab +/- Ipilimumab in...
Conference

Abstract B207: Nivolumab +/- Ipilimumab in patients with hypermutated cancers detected in blood: NIMBLE

Abstract

Abstract Background: During DNA replication, there is an increased risk for base substitution due to replicative errors caused by DNA polymerases, which have error rates of approximately 10-5 per base pair per cell division. One of the mechanisms to counteract these errors involves real-time proofreading via exonuclease activity present in both DNA polymerase ε, which synthesizes the leading strand and is encoded by POLE, and …

Authors

Rizvi N; Tang P; Bhardwaj N; Chan TA; Weber JS; Vickers M; Pintova S; Hirte H; Segal NH; Dhani N

Volume

7

Pagination

pp. b207-b207

Publisher

American Association for Cancer Research (AACR)

Publication Date

February 1, 2019

DOI

10.1158/2326-6074.cricimteatiaacr18-b207

Conference proceedings

Cancer Immunology Research

Issue

2_Supplement

ISSN

2326-6066